查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1612251

製藥業人工智慧市場：按產品、技術、部署模式、應用程式和最終用戶分類 - 2025-2030 年全球預測

Artificial Intelligence in Pharmaceutical Market by Offering (Hardware, Services, Software), Technology (Computer Vision, Machine Learning, Natural Language Processing), Deployment Mode, Application, End User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 187 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年人工智慧在製藥市場的價值為125.8億美元，預計到2024年將達到157.9億美元，複合年成長率為26.68%，到2030年將達到659億美元。

製藥業中的人工智慧 (AI) 包括使用先進的演算法、機器學習和資料分析來加速藥物發現、簡化臨床試驗、個人化醫療和增強製造流程。對人工智慧的需求源自於製藥業的大量資料和複雜性，需要創新的方法來提高效率、縮短上市時間並解決未滿足的醫療需求。應用範圍從疾病結果的預測建模和最佳化臨床試驗中的患者招募到自動化藥物製造的重複任務。最終用途包括希望利用人工智慧獲得競爭優勢的製藥公司、生物技術公司、研究機構和醫療保健提供者。關鍵的成長要素包括巨量資料可用性的不斷提高和運算能力的進步，推動了對人工智慧分析龐大資料集並得出有意義的見解的需求。此外，隨著專利到期和醫療保健成本的逼近，對具有成本效益的藥物開發的需求不斷成長，也推動了人工智慧的採用。擴大精準醫療、即時資料分析和改善病人參與平台的人工智慧能力存在機會。公司可以透過投資人才獲取、建立策略聯盟以及專注於道德人工智慧實施來利用這些優勢。然而，挑戰包括監管障礙、資料隱私問題以及將人工智慧系統整合到現有框架中的高成本。擁有人工智慧和製藥專業知識的熟練專業人士也存在人才缺口。基於人工智慧的生物標記發現和用於虛擬模擬的數位雙胞胎等創新具有突破的潛力。對人工智慧的道德使用的研究可以在保護患者資料的同時釋放市場機會。製藥人工智慧市場是動態的，經常受到監管政策、技術進步和協作研發工作的影響。為了在快速發展的環境中保持領先地位，公司需要保持敏捷性，擁抱開放創新模式和本土開發。

主要市場統計
基準年[2023] 125.8億美元
預測年份 [2024] 157.9億美元
預測年份 [2030] 659億美元
複合年成長率（%） 26.68%

市場動態：揭示製藥市場快速發展的人工智慧的關鍵市場洞察

供需的動態交互作用正在改變藥品領域的人工智慧市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時也能幫助企業了解消費行為及其對製造業的影響。

  • 市場促進因素
    • 對個人化醫療以改善治療結果的需求不斷成長
    • 利用人工智慧主導的方法來增強現有的藥物再利用策略
    • 加強生物醫學和臨床資料處理的資料日益成長
  • 市場限制因素
    • 開發和引入人工智慧解決方案需要大量初始投資
  • 市場機會
    • 介紹針對製藥業的人工智慧為基礎的創新解決方案
    • 大力投資人工智慧藥物發現研究
  • 市場挑戰
    • 資料隱私和安全問題

波特五力：駕馭製藥人工智慧市場的策略工具

波特的五力框架是了解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解外部對醫藥市場人工智慧的影響

外部宏觀環境因素在塑造製藥市場人工智慧的績效動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析 了解人工智慧藥品市場的競爭狀況

製藥市場人工智慧的詳細市場佔有率分析可以對供應商績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 製藥市場人工智慧定位矩陣供應商績效評估

FPNV 定位矩陣是評估製藥市場人工智慧供應商的關鍵工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

人工智慧在策略分析和藥物推薦市場的成功之路

對於旨在加強其在全球市場的影響力的公司來說，對製藥市場人工智慧的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：詳細檢視當前市場環境、主要企業的廣泛資料、評估其在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 對個人化醫療以改善治療結果的需求不斷成長
      • 利用人工智慧主導的方法來增強現有的藥物再利用策略
      • 加強生物醫學和臨床資料處理的需求日益成長
    • 抑制因素
      • 開發和實施人工智慧解決方案需要大量初始投資
    • 機會
      • 介紹針對製藥業的人工智慧為基礎的創新解決方案
      • 大量投資人工智慧藥物發現研究
    • 任務
      • 資料隱私和安全問題
  • 市場區隔分析
    • 我們提供什麼：由於功能和能力的改進，基於人工智慧的軟體的採用率有所提高
    • 技術：擴大機器學習技術在製藥領域的應用
    • 應用：利用人工智慧解決方案簡化臨床試驗流程
    • 最終用戶：製藥和生物技術公司大量採用人工智慧技術進行藥物發現和開發
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章 製藥領域的人工智慧市場：透過提供

  • 硬體
    • 記憶
    • 網路
    • 處理器
  • 服務
    • 部署與整合
    • 支援與維護
  • 軟體

第7章 製藥領域的人工智慧市場：依技術分類

  • 電腦視覺
  • 機器學習
  • 自然語言處理
  • 機器人流程自動化

第8章 醫藥人工智慧市場：依部署模式

  • 雲端基礎的解決方案
    • 混合雲端
    • 私有雲端
    • 公共雲端
  • 本地解決方案

第9章 製藥領域的人工智慧市場：依應用分類

  • 臨床試驗
    • 臨床資料管理
    • 病患招募
    • 安全監控
  • 醫藥開發
    • 配方開發
    • 臨床前研究
    • 原型設計
  • 藥物發現
    • 藥物測試
    • 先導化合物識別和最佳化
  • 個人化醫療
    • 生物標記發現
    • 基因組分析
    • 病人的病程

第 10 章 製藥業的人工智慧市場：依最終用戶分類

  • 合約調查機構
  • 醫療服務提供方
  • 製藥公司
  • 研究室

第11章 美洲製藥領域的人工智慧市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第12章亞太地區醫藥人工智慧市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第13章：歐洲、中東和非洲製藥業的人工智慧市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第14章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
    • 賽諾菲、Formation Bio 和 OpenAI 合作透過人工智慧整合改變藥物開發
    • NVIDIA BioNeMo 利用生成式 AI 模式轉變藥物發現，加速藥物創新。
    • 丹麥與突破性的 NVIDIA超級電腦合作，引領製藥領域的人工智慧創新
  • 戰略分析和建議

公司名單

  • AiCure, LLC
  • Aspen Technology Inc.
  • Atomwise Inc.
  • BenevolentAI SA
  • BioSymetrics Inc.
  • BPGbio Inc.
  • Butterfly Network, Inc.
  • Cloud Pharmaceuticals, Inc.
  • Cyclica by Recursion Pharmaceuticals, Inc.
  • Deargen Inc.
  • Deep Genomics Incorporated
  • Deloitte Touche Tohmatsu Limited
  • Euretos Services BV
  • Exscientia PLC
  • Google LLC
  • Insilico Medicine
  • Intel Corporation
  • International Business Machines Corporation
  • InveniAI LLC
  • Isomorphic Labs Limited
  • Microsoft Corporation
  • Novo Nordisk A/S
  • NVIDIA Corporation
  • Oracle Corporation
  • SANOFI WINTHROP INDUSTRIE
  • Turbine Ltd.
  • Viseven Europe OU
  • XtalPi Inc.
Product Code: MRR-A6768A62EE00

The Artificial Intelligence in Pharmaceutical Market was valued at USD 12.58 billion in 2023, expected to reach USD 15.79 billion in 2024, and is projected to grow at a CAGR of 26.68%, to USD 65.90 billion by 2030.

Artificial Intelligence (AI) in the pharmaceutical industry encompasses the use of advanced algorithms, machine learning, and data analytics to accelerate drug discovery, streamline clinical trials, personalize medicine, and enhance manufacturing processes. The necessity for AI arises from the enormous data and complexity in pharmaceuticals, requiring innovative approaches to improve efficiency, reduce time-to-market, and address unmet medical needs. Applications range from predictive modeling of disease outcomes and optimizing patient recruitment for trials to automating repetitive tasks in drug manufacturing. End-use scope includes pharmaceutical companies, biotech firms, research institutions, and healthcare providers seeking to harness AI for competitive advantage. Key growth factors include the increasing availability of big data and advancements in computational power, driving demand for AI to analyze vast datasets for meaningful insights. Moreover, the rising need for cost-effective drug development in the face of looming patent expirations and healthcare costs further fuels AI adoption. Opportunities lie in expanding AI capabilities in precision medicine, real-time data analytics, and improving patient engagement platforms. Companies can capitalize on these by investing in talent acquisition, forming strategic alliances, and maintaining a focus on ethical AI deployment. However, challenges include regulatory hurdles, data privacy concerns, and high costs of integrating AI systems within existing frameworks. There's also a talent gap for skilled professionals adept in both AI and pharmaceuticals. Innovations in AI-driven biomarker discovery and digital twins for virtual simulations hold promise for breakthroughs. Research on ethical AI usage can safeguard patient data while unlocking market opportunity. The AI in pharmaceutical market is dynamic, often influenced by regulatory policies, technological advancements, and collaborative R&D efforts. Companies must remain agile, embracing both open innovation models and proprietary developments to stay ahead in a rapidly evolving landscape.

KEY MARKET STATISTICS
Base Year [2023] USD 12.58 billion
Estimated Year [2024] USD 15.79 billion
Forecast Year [2030] USD 65.90 billion
CAGR (%) 26.68%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Artificial Intelligence in Pharmaceutical Market

The Artificial Intelligence in Pharmaceutical Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Growing demand for personalized medicine to improve treatment outcomes
    • Utilization of AI-driven approaches to enhance existing drug repurposing strategies
    • Increasing need to enhance the processing of biomedical and clinical data
  • Market Restraints
    • High initial investment for developing and implementing AI solutions
  • Market Opportunities
    • Introduction of innovative AI-based solutions for pharmaceutical industry
    • Significant investments for AI drug discovery research
  • Market Challenges
    • Concerns regarding data privacy and security

Porter's Five Forces: A Strategic Tool for Navigating the Artificial Intelligence in Pharmaceutical Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Artificial Intelligence in Pharmaceutical Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Artificial Intelligence in Pharmaceutical Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Artificial Intelligence in Pharmaceutical Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Artificial Intelligence in Pharmaceutical Market

A detailed market share analysis in the Artificial Intelligence in Pharmaceutical Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Artificial Intelligence in Pharmaceutical Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Artificial Intelligence in Pharmaceutical Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Artificial Intelligence in Pharmaceutical Market

A strategic analysis of the Artificial Intelligence in Pharmaceutical Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Artificial Intelligence in Pharmaceutical Market, highlighting leading vendors and their innovative profiles. These include AiCure, LLC, Aspen Technology Inc., Atomwise Inc., BenevolentAI SA, BioSymetrics Inc., BPGbio Inc., Butterfly Network, Inc., Cloud Pharmaceuticals, Inc., Cyclica by Recursion Pharmaceuticals, Inc., Deargen Inc., Deep Genomics Incorporated, Deloitte Touche Tohmatsu Limited, Euretos Services BV, Exscientia PLC, Google LLC, Insilico Medicine, Intel Corporation, International Business Machines Corporation, InveniAI LLC, Isomorphic Labs Limited, Microsoft Corporation, Novo Nordisk A/S, NVIDIA Corporation, Oracle Corporation, SANOFI WINTHROP INDUSTRIE, Turbine Ltd., Viseven Europe OU, and XtalPi Inc..

Market Segmentation & Coverage

This research report categorizes the Artificial Intelligence in Pharmaceutical Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Offering, market is studied across Hardware, Services, and Software. The Hardware is further studied across Memory, Network, and Processor. The Services is further studied across Deployment & Integration and Support & Maintenance.
  • Based on Technology, market is studied across Computer Vision, Machine Learning, Natural Language Processing, and Robotic Process Automation.
  • Based on Deployment Mode, market is studied across Cloud-Based Solutions and On-Premise Solutions. The Cloud-Based Solutions is further studied across Hybrid Cloud, Private Cloud, and Public Cloud.
  • Based on Application, market is studied across Clinical Trials, Drug Development, Drug Discovery, and Personalized Medicine. The Clinical Trials is further studied across Clinical Data Management, Patient Recruitment, and Safety Monitoring. The Drug Development is further studied across Formulation Development, Preclinical Studies, and Prototype Design. The Drug Discovery is further studied across Drug Screening and Lead Identification & Optimization. The Personalized Medicine is further studied across Biomarker Discovery, Genomic Analysis, and Patient Disease Journey.
  • Based on End User, market is studied across Contract Research Organizations, Healthcare Providers, Pharmaceutical Companies, and Research Laboratories.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing demand for personalized medicine to improve treatment outcomes
      • 5.1.1.2. Utilization of AI-driven approaches to enhance existing drug repurposing strategies
      • 5.1.1.3. Increasing need to enhance the processing of biomedical and clinical data
    • 5.1.2. Restraints
      • 5.1.2.1. High initial investment for developing and implementing AI solutions
    • 5.1.3. Opportunities
      • 5.1.3.1. Introduction of innovative AI-based solutions for pharmaceutical industry
      • 5.1.3.2. Significant investments for AI drug discovery research
    • 5.1.4. Challenges
      • 5.1.4.1. Concerns regarding data privacy and security
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Offerings: Growing AI-based software adoption owing to its improved functionality & features
    • 5.2.2. Technology: Increasing utilization of machine learning technology in the pharmaceutical sector
    • 5.2.3. Applications: Improving the efficiency of clinical trial process through AI solutions
    • 5.2.4. End-users: Significant implementation of AI technologies by pharma & biotech companies for drug discovery & development
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Artificial Intelligence in Pharmaceutical Market, by Offering

  • 6.1. Introduction
  • 6.2. Hardware
    • 6.2.1. Memory
    • 6.2.2. Network
    • 6.2.3. Processor
  • 6.3. Services
    • 6.3.1. Deployment & Integration
    • 6.3.2. Support & Maintenance
  • 6.4. Software

7. Artificial Intelligence in Pharmaceutical Market, by Technology

  • 7.1. Introduction
  • 7.2. Computer Vision
  • 7.3. Machine Learning
  • 7.4. Natural Language Processing
  • 7.5. Robotic Process Automation

8. Artificial Intelligence in Pharmaceutical Market, by Deployment Mode

  • 8.1. Introduction
  • 8.2. Cloud-Based Solutions
    • 8.2.1. Hybrid Cloud
    • 8.2.2. Private Cloud
    • 8.2.3. Public Cloud
  • 8.3. On-Premise Solutions

9. Artificial Intelligence in Pharmaceutical Market, by Application

  • 9.1. Introduction
  • 9.2. Clinical Trials
    • 9.2.1. Clinical Data Management
    • 9.2.2. Patient Recruitment
    • 9.2.3. Safety Monitoring
  • 9.3. Drug Development
    • 9.3.1. Formulation Development
    • 9.3.2. Preclinical Studies
    • 9.3.3. Prototype Design
  • 9.4. Drug Discovery
    • 9.4.1. Drug Screening
    • 9.4.2. Lead Identification & Optimization
  • 9.5. Personalized Medicine
    • 9.5.1. Biomarker Discovery
    • 9.5.2. Genomic Analysis
    • 9.5.3. Patient Disease Journey

10. Artificial Intelligence in Pharmaceutical Market, by End User

  • 10.1. Introduction
  • 10.2. Contract Research Organizations
  • 10.3. Healthcare Providers
  • 10.4. Pharmaceutical Companies
  • 10.5. Research Laboratories

11. Americas Artificial Intelligence in Pharmaceutical Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific Artificial Intelligence in Pharmaceutical Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa Artificial Intelligence in Pharmaceutical Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2023
  • 14.2. FPNV Positioning Matrix, 2023
  • 14.3. Competitive Scenario Analysis
    • 14.3.1. Sanofi, Formation Bio, and OpenAI collaborate to transform drug development through AI integration
    • 14.3.2. NVIDIA BioNeMo transforms drug discovery with generative AI models to accelerate pharmaceutical innovation
    • 14.3.3. Denmark pioneers AI innovation in pharmaceuticals with groundbreaking NVIDIA supercomputer collaboration
  • 14.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AiCure, LLC
  • 2. Aspen Technology Inc.
  • 3. Atomwise Inc.
  • 4. BenevolentAI SA
  • 5. BioSymetrics Inc.
  • 6. BPGbio Inc.
  • 7. Butterfly Network, Inc.
  • 8. Cloud Pharmaceuticals, Inc.
  • 9. Cyclica by Recursion Pharmaceuticals, Inc.
  • 10. Deargen Inc.
  • 11. Deep Genomics Incorporated
  • 12. Deloitte Touche Tohmatsu Limited
  • 13. Euretos Services BV
  • 14. Exscientia PLC
  • 15. Google LLC
  • 16. Insilico Medicine
  • 17. Intel Corporation
  • 18. International Business Machines Corporation
  • 19. InveniAI LLC
  • 20. Isomorphic Labs Limited
  • 21. Microsoft Corporation
  • 22. Novo Nordisk A/S
  • 23. NVIDIA Corporation
  • 24. Oracle Corporation
  • 25. SANOFI WINTHROP INDUSTRIE
  • 26. Turbine Ltd.
  • 27. Viseven Europe OU
  • 28. XtalPi Inc.

LIST OF FIGURES

  • FIGURE 1. ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET RESEARCH PROCESS
  • FIGURE 2. ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY OFFERING, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY OFFERING, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY TECHNOLOGY, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY TECHNOLOGY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DEPLOYMENT MODE, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DEPLOYMENT MODE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY END USER, 2023 VS 2030 (%)
  • FIGURE 15. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. AMERICAS ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. AMERICAS ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. UNITED STATES ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 19. UNITED STATES ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. ASIA-PACIFIC ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 23. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 24. ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 25. ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET DYNAMICS
  • TABLE 7. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY HARDWARE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY MEMORY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY NETWORK, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY PROCESSOR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY HARDWARE, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY SERVICES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DEPLOYMENT & INTEGRATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY SUPPORT & MAINTENANCE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY SOFTWARE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY COMPUTER VISION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY MACHINE LEARNING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY NATURAL LANGUAGE PROCESSING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY ROBOTIC PROCESS AUTOMATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DEPLOYMENT MODE, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY CLOUD-BASED SOLUTIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY HYBRID CLOUD, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY PRIVATE CLOUD, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY PUBLIC CLOUD, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY CLOUD-BASED SOLUTIONS, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY ON-PREMISE SOLUTIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY CLINICAL TRIALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY CLINICAL DATA MANAGEMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY PATIENT RECRUITMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY SAFETY MONITORING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DRUG DEVELOPMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 37. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY FORMULATION DEVELOPMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 38. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY PRECLINICAL STUDIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 39. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY PROTOTYPE DESIGN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 40. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 41. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DRUG DISCOVERY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 42. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DRUG SCREENING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 43. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY LEAD IDENTIFICATION & OPTIMIZATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 44. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 45. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY PERSONALIZED MEDICINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 46. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY BIOMARKER DISCOVERY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 47. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY GENOMIC ANALYSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 48. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY PATIENT DISEASE JOURNEY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 49. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2030 (USD MILLION)
  • TABLE 50. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 51. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 52. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY HEALTHCARE PROVIDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 53. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 54. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY RESEARCH LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 55. AMERICAS ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 56. AMERICAS ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY HARDWARE, 2018-2030 (USD MILLION)
  • TABLE 57. AMERICAS ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 58. AMERICAS ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 59. AMERICAS ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DEPLOYMENT MODE, 2018-2030 (USD MILLION)
  • TABLE 60. AMERICAS ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY CLOUD-BASED SOLUTIONS, 2018-2030 (USD MILLION)
  • TABLE 61. AMERICAS ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 62. AMERICAS ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 63. AMERICAS ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 64. AMERICAS ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 65. AMERICAS ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2030 (USD MILLION)
  • TABLE 66. AMERICAS ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 67. AMERICAS ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 68. ARGENTINA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 69. ARGENTINA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY HARDWARE, 2018-2030 (USD MILLION)
  • TABLE 70. ARGENTINA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 71. ARGENTINA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 72. ARGENTINA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DEPLOYMENT MODE, 2018-2030 (USD MILLION)
  • TABLE 73. ARGENTINA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY CLOUD-BASED SOLUTIONS, 2018-2030 (USD MILLION)
  • TABLE 74. ARGENTINA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 75. ARGENTINA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 76. ARGENTINA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 77. ARGENTINA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 78. ARGENTINA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2030 (USD MILLION)
  • TABLE 79. ARGENTINA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 80. BRAZIL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 81. BRAZIL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY HARDWARE, 2018-2030 (USD MILLION)
  • TABLE 82. BRAZIL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 83. BRAZIL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 84. BRAZIL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DEPLOYMENT MODE, 2018-2030 (USD MILLION)
  • TABLE 85. BRAZIL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY CLOUD-BASED SOLUTIONS, 2018-2030 (USD MILLION)
  • TABLE 86. BRAZIL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 87. BRAZIL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 88. BRAZIL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 89. BRAZIL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 90. BRAZIL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2030 (USD MILLION)
  • TABLE 91. BRAZIL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 92. CANADA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 93. CANADA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY HARDWARE, 2018-2030 (USD MILLION)
  • TABLE 94. CANADA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 95. CANADA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 96. CANADA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DEPLOYMENT MODE, 2018-2030 (USD MILLION)
  • TABLE 97. CANADA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY CLOUD-BASED SOLUTIONS, 2018-2030 (USD MILLION)
  • TABLE 98. CANADA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 99. CANADA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 100. CANADA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 101. CANADA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 102. CANADA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2030 (USD MILLION)
  • TABLE 103. CANADA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 104. MEXICO ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 105. MEXICO ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY HARDWARE, 2018-2030 (USD MILLION)
  • TABLE 106. MEXICO ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 107. MEXICO ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 108. MEXICO ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DEPLOYMENT MODE, 2018-2030 (USD MILLION)
  • TABLE 109. MEXICO ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY CLOUD-BASED SOLUTIONS, 2018-2030 (USD MILLION)
  • TABLE 110. MEXICO ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 111. MEXICO ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 112. MEXICO ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 113. MEXICO ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 114. MEXICO ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2030 (USD MILLION)
  • TABLE 115. MEXICO ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 116. UNITED STATES ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 117. UNITED STATES ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY HARDWARE, 2018-2030 (USD MILLION)
  • TABLE 118. UNITED STATES ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 119. UNITED STATES ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 120. UNITED STATES ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DEPLOYMENT MODE, 2018-2030 (USD MILLION)
  • TABLE 121. UNITED STATES ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY CLOUD-BASED SOLUTIONS, 2018-2030 (USD MILLION)
  • TABLE 122. UNITED STATES ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 123. UNITED STATES ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 124. UNITED STATES ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 125. UNITED STATES ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 126. UNITED STATES ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2030 (USD MILLION)
  • TABLE 127. UNITED STATES ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 128. UNITED STATES ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 129. ASIA-PACIFIC ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 130. ASIA-PACIFIC ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY HARDWARE, 2018-2030 (USD MILLION)
  • TABLE 131. ASIA-PACIFIC ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 132. ASIA-PACIFIC ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 133. ASIA-PACIFIC ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DEPLOYMENT MODE, 2018-2030 (USD MILLION)
  • TABLE 134. ASIA-PACIFIC ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY CLOUD-BASED SOLUTIONS, 2018-2030 (USD MILLION)
  • TABLE 135. ASIA-PACIFIC ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 136. ASIA-PACIFIC ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 137. ASIA-PACIFIC ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 138. ASIA-PACIFIC ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 139. ASIA-PACIFIC ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2030 (USD MILLION)
  • TABLE 140. ASIA-PACIFIC ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 141. ASIA-PACIFIC ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 142. AUSTRALIA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 143. AUSTRALIA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY HARDWARE, 2018-2030 (USD MILLION)
  • TABLE 144. AUSTRALIA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 145. AUSTRALIA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 146. AUSTRALIA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DEPLOYMENT MODE, 2018-2030 (USD MILLION)
  • TABLE 147. AUSTRALIA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY CLOUD-BASED SOLUTIONS, 2018-2030 (USD MILLION)
  • TABLE 148. AUSTRALIA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 149. AUSTRALIA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 150. AUSTRALIA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 151. AUSTRALIA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 152. AUSTRALIA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2030 (USD MILLION)
  • TABLE 153. AUSTRALIA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 154. CHINA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 155. CHINA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY HARDWARE, 2018-2030 (USD MILLION)
  • TABLE 156. CHINA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 157. CHINA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 158. CHINA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DEPLOYMENT MODE, 2018-2030 (USD MILLION)
  • TABLE 159. CHINA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY CLOUD-BASED SOLUTIONS, 2018-2030 (USD MILLION)
  • TABLE 160. CHINA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 161. CHINA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 162. CHINA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 163. CHINA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 164. CHINA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2030 (USD MILLION)
  • TABLE 165. CHINA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 166. INDIA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 167. INDIA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY HARDWARE, 2018-2030 (USD MILLION)
  • TABLE 168. INDIA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 169. INDIA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 170. INDIA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DEPLOYMENT MODE, 2018-2030 (USD MILLION)
  • TABLE 171. INDIA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY CLOUD-BASED SOLUTIONS, 2018-2030 (USD MILLION)
  • TABLE 172. INDIA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 173. INDIA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 174. INDIA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 175. INDIA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 176. INDIA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2030 (USD MILLION)
  • TABLE 177. INDIA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 178. INDONESIA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 179. INDONESIA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY HARDWARE, 2018-2030 (USD MILLION)
  • TABLE 180. INDONESIA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 181. INDONESIA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 182. INDONESIA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DEPLOYMENT MODE, 2018-2030 (USD MILLION)
  • TABLE 183. INDONESIA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY CLOUD-BASED SOLUTIONS, 2018-2030 (USD MILLION)
  • TABLE 184. INDONESIA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 185. INDONESIA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 186. INDONESIA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 187. INDONESIA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 188. INDONESIA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2030 (USD MILLION)
  • TABLE 189. INDONESIA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 190. JAPAN ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 191. JAPAN ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY HARDWARE, 2018-2030 (USD MILLION)
  • TABLE 192. JAPAN ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 193. JAPAN ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 194. JAPAN ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DEPLOYMENT MODE, 2018-2030 (USD MILLION)
  • TABLE 195. JAPAN ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY CLOUD-BASED SOLUTIONS, 2018-2030 (USD MILLION)
  • TABLE 196. JAPAN ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 197. JAPAN ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 198. JAPAN ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 199. JAPAN ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 200. JAPAN ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2030 (USD MILLION)
  • TABLE 201. JAPAN ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 202. MALAYSIA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 203. MALAYSIA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY HARDWARE, 2018-2030 (USD MILLION)
  • TABLE 204. MALAYSIA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 205. MALAYSIA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 206. MALAYSIA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DEPLOYMENT MODE, 2018-2030 (USD MILLION)
  • TABLE 207. MALAYSIA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY CLOUD-BASED SOLUTIONS, 2018-2030 (USD MILLION)
  • TABLE 208. MALAYSIA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 209. MALAYSIA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 210. MALAYSIA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 211. MALAYSIA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 212. MALAYSIA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2030 (USD MILLION)
  • TABLE 213. MALAYSIA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 214. PHILIPPINES ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 215. PHILIPPINES ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY HARDWARE, 2018-2030 (USD MILLION)
  • TABLE 216. PHILIPPINES ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 217. PHILIPPINES ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 218. PHILIPPINES ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DEPLOYMENT MODE, 2018-2030 (USD MILLION)
  • TABLE 219. PHILIPPINES ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY CLOUD-BASED SOLUTIONS, 2018-2030 (USD MILLION)
  • TABLE 220. PHILIPPINES ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 221. PHILIPPINES ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 222. PHILIPPINES ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 223. PHILIPPINES ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 224. PHILIPPINES ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2030 (USD MILLION)
  • TABLE 225. PHILIPPINES ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 226. SINGAPORE ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 227. SINGAPORE ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY HARDWARE, 2018-2030 (USD MILLION)
  • TABLE 228. SINGAPORE ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 229. SINGAPORE ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 230. SINGAPORE ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DEPLOYMENT MODE, 2018-2030 (USD MILLION)
  • TABLE 231. SINGAPORE ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY CLOUD-BASED SOLUTIONS, 2018-2030 (USD MILLION)
  • TABLE 232. SINGAPORE ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 233. SINGAPORE ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 234. SINGAPORE ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 235. SINGAPORE ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 236. SINGAPORE ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2030 (USD MILLION)
  • TABLE 237. SINGAPORE ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 238. SOUTH KOREA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 239. SOUTH KOREA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY HARDWARE, 2018-2030 (USD MILLION)
  • TABLE 240. SOUTH KOREA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 241. SOUTH KOREA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 242. SOUTH KOREA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DEPLOYMENT MODE, 2018-2030 (USD MILLION)
  • TABLE 243. SOUTH KOREA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY CLOUD-BASED SOLUTIONS, 2018-2030 (USD MILLION)
  • TABLE 244. SOUTH KOREA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 245. SOUTH KOREA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 246. SOUTH KOREA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 247. SOUTH KOREA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 248. SOUTH KOREA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2030 (USD MILLION)
  • TABLE 249. SOUTH KOREA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 250. TAIWAN ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 251. TAIWAN ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY HARDWARE, 2018-2030 (USD MILLION)
  • TABLE 252. TAIWAN ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 253. TAIWAN ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 254. TAIWAN ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DEPLOYMENT MODE, 2018-2030 (USD MILLION)
  • TABLE 255. TAIWAN ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY CLOUD-BASED SOLUTIONS, 2018-2030 (USD MILLION)
  • TABLE 256. TAIWAN ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 257. TAIWAN ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 258. TAIWAN ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 259. TAIWAN ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 260. TAIWAN ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2030 (USD MILLION)
  • TABLE 261. TAIWAN ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 262. THAILAND ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 263. THAILAND ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY HARDWARE, 2018-2030 (USD MILLION)
  • TABLE 264. THAILAND ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 265. THAILAND ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 266. THAILAND ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DEPLOYMENT MODE, 2018-2030 (USD MILLION)
  • TABLE 267. THAILAND ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY CLOUD-BASED SOLUTIONS, 2018-2030 (USD MILLION)
  • TABLE 268. THAILAND ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 269. THAILAND ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 270. THAILAND ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 271. THAILAND ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 272. THAILAND ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2030 (USD MILLION)
  • TABLE 273. THAILAND ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 274. VIETNAM ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 275. VIETNAM ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY HARDWARE, 2018-2030 (USD MILLION)
  • TABLE 276. VIETNAM ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 277. VIETNAM ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 278. VIETNAM ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DEPLOYMENT MODE, 2018-2030 (USD MILLION)
  • TABLE 279. VIETNAM ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY CLOU